Arrowhead Pharmaceuticals vs Repligen
Arrowhead Pharmaceuticals reported revenue of $829 million in fiscal 2025, about the same as Repligen's $738 million in fiscal 2025. Arrowhead Pharmaceuticals' revenue grew 23258.2% in its latest year, and Repligen's grew 16.4%. Arrowhead Pharmaceuticals had an operating margin of 11.9%, against 7.5% at Repligen. Free cash flow was $157 million at Arrowhead Pharmaceuticals and $94 million at Repligen. Their fiscal years end in different months (September 30 and December 31), so the periods don't line up exactly.
Side by side
| Arrowhead Pharmaceuticals | Repligen | |
|---|---|---|
| Latest fiscal year | FY2025, Sep 30, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $829M | $738M |
| Revenue growth | 23,258.2% | 16.4% |
| Revenue growth a year, last 5 years | 56.6% | 15.0% |
| Gross margin | — | 52.3% |
| Operating margin | 11.9% | 7.5% |
| Net margin | −0.2% | 6.6% |
| Free cash flow | $157M | $94M |
| Free cash flow margin | 18.9% | 12.7% |
| Return on capital | — | 2.4% |
| Net debt to EBITDA | −5.5x | −1.7x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 11.7% | — |
| Last close | $58.98 | $180.17 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $37.3 million | sold $14.2 million |
| Piotroski F-score | 5 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Arrowhead PharmaceuticalsRepligen
Operating margin
Percent of revenue
Arrowhead PharmaceuticalsRepligen
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arrowhead PharmaceuticalsRepligen
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arrowhead Pharmaceuticals and Repligen pages.